Your browser doesn't support javascript.
loading
TransCon IL-2 ß/γ: a novel long-acting prodrug with sustained release of an IL-2Rß/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
Rosen, David B; Kvarnhammar, Anne Månsson; Laufer, Burkhardt; Knappe, Thomas; Karlsson, Jens Jakob; Hong, Enping; Lee, Yu-Chi; Thakar, Dhruv; Zúñiga, Luis Alejandro; Bang, Kathy; Sabharwal, Simran Singh; Uppal, Karan; Olling, Janne Damm; Kjaergaard, Kristian; Kurpiers, Thomas; Schnabel, Meike; Reich, Diana; Glock, Philipp; Zettler, Joachim; Krusch, Mathias; Bernhard, Ana; Heinig, Stefan; Konjik, Valentino; Wegge, Thomas; Hehn, Yvonne; Killian, Steffen; Viet, Laura; Runz, Josefine; Faltinger, Frank; Tabrizi, Mohammad; Abel, Kristin Laura; Breinholt, Vibeke Miller; Singel, Stina M; Sprogøe, Kennett; Punnonen, Juha.
Affiliation
  • Rosen DB; Ascendis Pharma Inc, Redwood City, California, USA drn@ascendispharma.com.
  • Kvarnhammar AM; Ascendis Pharma A/S, Hellerup, Denmark.
  • Laufer B; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Knappe T; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Karlsson JJ; Ascendis Pharma A/S, Hellerup, Denmark.
  • Hong E; Ascendis Pharma Inc, Redwood City, California, USA.
  • Lee YC; Ascendis Pharma Inc, Redwood City, California, USA.
  • Thakar D; Ascendis Pharma Inc, Redwood City, California, USA.
  • Zúñiga LA; Ascendis Pharma Inc, Redwood City, California, USA.
  • Bang K; Ascendis Pharma Inc, Redwood City, California, USA.
  • Sabharwal SS; Ascendis Pharma Inc, Redwood City, California, USA.
  • Uppal K; Ascendis Pharma Inc, Redwood City, California, USA.
  • Olling JD; Ascendis Pharma A/S, Hellerup, Denmark.
  • Kjaergaard K; Ascendis Pharma A/S, Hellerup, Denmark.
  • Kurpiers T; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Schnabel M; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Reich D; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Glock P; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Zettler J; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Krusch M; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Bernhard A; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Heinig S; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Konjik V; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Wegge T; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Hehn Y; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Killian S; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Viet L; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Runz J; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Faltinger F; Ascendis Pharma GmbH, Heidelberg, Germany.
  • Tabrizi M; Ascendis Pharma Inc, Redwood City, California, USA.
  • Abel KL; Ascendis Pharma A/S, Hellerup, Denmark.
  • Breinholt VM; Ascendis Pharma A/S, Hellerup, Denmark.
  • Singel SM; Ascendis Pharma Inc, Palo Alto, California, USA.
  • Sprogøe K; Ascendis Pharma A/S, Hellerup, Denmark.
  • Punnonen J; Ascendis Pharma Inc, Redwood City, California, USA.
J Immunother Cancer ; 10(7)2022 07.
Article in En | MEDLINE | ID: mdl-35817480
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prodrugs / Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Animals / Humans Language: En Journal: J Immunother Cancer Year: 2022 Document type: Article Affiliation country: United States Country of publication: United kingdom
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Prodrugs / Neoplasms Type of study: Clinical_trials / Prognostic_studies Limits: Animals / Humans Language: En Journal: J Immunother Cancer Year: 2022 Document type: Article Affiliation country: United States Country of publication: United kingdom